Related Experiment Videos
[Immunomodulator treatment of multibacillary leprosy using extracts of microbial ribosomes]
P Saint-André1, G Baquillon, M David
1Association Franćaise des Fondations Raoul Follerau, Paris, France.
Abstract:
Ribomunyl can in practice be profitably included in the range of immunostimulants, but it requires weekly injections and hence surveillance that will also enable any adverse reactions to be monitored. Its action and tolerance after polychemotherapy have still to be studied. On the basis of our experience, we feel that only isoprinosine, whose effectiveness and good tolerance we have demonstrated, can be used for self-treatment in a mass campaign.
Insights
Ribomunyl may be a useful immunostimulant but requires medical monitoring due to weekly injections. Isoprinosine shows effectiveness and good tolerance, making it suitable for self-treatment in mass campaigns.
Area of Science:
- Immunology
- Pharmacology
Context:
- Evaluation of immunostimulant drugs for therapeutic use.
- Assessment of drug administration methods and patient monitoring requirements.
Purpose:
- To compare the efficacy and safety of Ribomunyl and Isoprinosine as immunostimulants.
- To determine the suitability of these drugs for self-administration in public health initiatives.
Summary:
- Ribomunyl, while a potential immunostimulant, necessitates weekly injections and close monitoring for adverse reactions. Its effects post-polychemotherapy require further investigation.
- Isoprinosine demonstrated effectiveness and good tolerance, indicating its potential for self-treatment during mass campaigns.
Impact:
- Provides insights into the practical application and limitations of Ribomunyl.
- Highlights Isoprinosine as a viable option for self-administered immunostimulation in large-scale health programs.